Through this approval, Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease.
The company’s standalone net profit surged 60.1% to Rs 56.08 crore on 35.8% increase in revenue from operations to Rs 526.31 crore in Q1 FY26 over Q1 FY25.
The scrip advanced 1.12% to settle at Rs 9324.70 on the BSE.